Journal for ImmunoTherapy of Cancer (Nov 2020)
760 Trough levels of ipilimumab in serum as a potential predictive biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab
Abstract
No abstracts available.
Journal for ImmunoTherapy of Cancer (Nov 2020)